Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Urovant

- PMLiVE

Sumitomo Dainippon goes big on biotech with $3bn Roivant deal

Could acquire up to 11 Roivant spinouts

- PMLiVE

Urovant slips on phase 3 incontinence drug data

Underwhelming results send shares down

- PMLiVE

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

FDA rejects Waylivra, Roivant group continues gene therapy drive, UK biotech gains £637k

- PMLiVE

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

Big departure from repurposing - Spark's Fraser Wright comes on board

- PMLiVE

After Axovant shock, Roivant pens diabetes deal with Poxel

Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal

- PMLiVE

Roivant gets $1.1bn investment from Japan’s SoftBank

The fund will launch new subsidiaries, says the biotech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links